Atherosclerosis

What Is Atherosclerosis?

Atherosclerosis is a lipoprotein driven inflammatory disorder that leads to plaque formation at specific sites within the arterial tree throughout the body.¹

Inflammation plays a pivotal role across all phases of the disease, from the earliest fatty streak lesion formation through to acute cardiovascular events triggered by plaque rupture.¹

Rather than a simple, passive buildup of fat within artery walls, atherosclerosis represents an active, ongoing inflammatory process involving multiple cell types and biological pathways.¹

Inflammation plays a pivotal role in all phases of atherosclerosis, from the fatty streak lesion formation to the acute coronary event due to vulnerable plaque rupture.
National Center for Biotechnology Information

Symptoms

A hemodynamically non significant coronary plaque can rupture and produce a serious cardiac event long before it causes meaningful artery narrowing or noticeable symptoms such as chest pain.²

This means atherosclerosis often progresses silently for years, with many patients experiencing no warning symptoms whatsoever before a sudden, serious cardiovascular event occurs.

When symptoms do develop, they typically reflect reduced blood flow to a specific organ or tissue, varying considerably depending on which arteries are most significantly affected.

Causes

Rupture prone plaques typically have the appearance of thin cap fibroatheromas, characterized by increased overall plaque size and a large, lipid rich necrotic core covered by a notably thin fibrous cap.³

These vulnerable plaques become infiltrated with macrophages and other inflammatory cells, which participate in lipoprotein uptake and metabolism while also producing enzymes and toxic byproducts that progressively weaken the fibrous cap.³

This weakening process ultimately increases the likelihood of plaque rupture, the event that directly triggers many acute cardiovascular emergencies such as heart attack and stroke.³

Risk Factors

Systemic factors correlating with plaque rupture include altered blood flow characteristics, increased blood clotting tendency, heightened systemic inflammation, and recurrent infections.⁴

These systemic factors frequently interact with well established traditional risk factors, including elevated cholesterol, smoking, and diabetes, to further increase overall cardiovascular risk.⁴

High sensitivity C reactive protein, a simple downstream marker of inflammation, has emerged as a major independent cardiovascular risk factor beyond traditional cholesterol measurements alone.⁵

Complications

C reactive protein has been shown to induce a blood clot promoting state within the body and predicts the progression of atherosclerosis when measured across various sites within the arterial tree.⁵

Vulnerable plaques represent the underlying culprit behind the large majority of acute coronary syndromes, making their identification a major focus of modern cardiovascular research.⁶

Advances in diagnostic imaging continue to improve clinicians’ ability to identify vulnerable plaque characteristics before rupture occurs, offering the potential for more proactive, preventive intervention.⁷

Treatment

Statin medications remain a cornerstone of atherosclerosis treatment, working to lower cholesterol levels while also providing meaningful anti inflammatory benefits within artery walls.

PCSK9 inhibitors, a newer class of cholesterol lowering medication, work by decreasing circulating PCSK9 protein, which elevates LDL receptor levels and promotes increased LDL cholesterol uptake by the liver.⁸

Combination therapy using statins alongside PCSK9 inhibitors has been shown to more effectively stabilize atherosclerotic plaques compared to statin therapy used alone, reducing markers of vascular inflammation within the artery wall.⁹

Prevention

Managing traditional risk factors, including cholesterol levels, blood pressure, smoking, and diabetes, remains the foundation of atherosclerosis prevention efforts.

Because systemic inflammation independently contributes to plaque vulnerability, addressing sources of chronic inflammation may offer additional cardiovascular protection beyond cholesterol management alone.⁴

Regular cardiovascular risk assessment, potentially incorporating inflammatory markers such as high sensitivity C reactive protein, supports more comprehensive, individualized prevention strategies.⁵

Why Visual Communication Matters for Atherosclerosis

Explaining how inflammation transforms a stable arterial plaque into a dangerous, rupture prone lesion requires visuals that make this dynamic biological process clear and memorable.

Pharmaceutical companies, cardiology practices, and patient education organizations rely on precise illustration and animation to explain atherosclerosis biology and treatment.

• Illustrating plaque formation and progression within artery walls
• Animating the transition from stable to vulnerable, rupture prone plaque
• Explaining the role of inflammation and macrophages in plaque instability
• Visualizing the mechanism of action of statin and PCSK9 inhibitor therapy
• Supporting patient education on risk factor management
• Creating training materials for cardiology clinicians

How Biotic Artlab Supports Atherosclerosis Communication

We work with pharmaceutical companies, cardiology practices, and healthcare organizations to create scientifically accurate visuals that make atherosclerosis easier to understand.

• Custom 3D animations of plaque formation and vulnerable plaque biology
• Detailed illustrations of inflammatory cell activity within artery walls
• Mechanism of action animations for statin and PCSK9 inhibitor therapy
• Patient facing materials on risk factor management and prevention
• Clinical training content for cardiology teams
• Conference presentations and marketing visuals for cardiovascular audiences

Frequently Asked Questions

What is atherosclerosis?

It is an inflammatory disorder driven by lipoproteins that leads to plaque formation within artery walls.¹

Why can atherosclerosis be dangerous without symptoms?

Plaques can rupture and cause serious events even before they cause noticeable artery narrowing or symptoms.²

What makes a plaque vulnerable to rupture?

A large lipid core covered by a thin fibrous cap, infiltrated with inflammatory cells, increases rupture risk.³

What role does CRP play in atherosclerosis?

High sensitivity CRP is an inflammatory marker that independently predicts atherosclerosis progression and cardiovascular risk.⁵

How is atherosclerosis treated?

Statins and PCSK9 inhibitors are commonly used to lower cholesterol and stabilize arterial plaque.⁸

Can atherosclerosis be prevented?

Managing cholesterol, blood pressure, smoking, and inflammation can significantly reduce risk.⁴

Have a Project in Mind? Contact Us.

If you are developing patient education materials, clinical training content, or marketing visuals related to atherosclerosis, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.

References

1. National Center for Biotechnology Information. Atherosclerotic Plaque Biomarkers, Beyond the Horizon of the Vulnerable Plaque.
2. National Center for Biotechnology Information. The Vulnerable Plaque, the Real Villain in Acute Coronary Syndromes.
3. National Center for Biotechnology Information. Vulnerable Plaque, Characteristics, Detection, and Potential Therapies.
4. National Center for Biotechnology Information. Vulnerable Plaque, From Bench to Bedside, Local Pacification Versus Systemic Therapy.
5. National Center for Biotechnology Information. CRP and the Risk of Atherosclerotic Events.
6. National Center for Biotechnology Information. Residual Inflammatory Risk and Vulnerable Plaque in the Carotid Artery in Patients With Ischemic Stroke.
7. National Center for Biotechnology Information. Current Advances in the Diagnostic Imaging of Atherosclerosis, Insights Into the Pathophysiology of Vulnerable Plaque.
8. National Center for Biotechnology Information. Endothelial Cell-Derived PCSK9 in Atherosclerosis, Pathophysiological Roles and Therapeutic Perspectives.
9. National Center for Biotechnology Information. Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients With Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque.

Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, or individualized advice from a qualified healthcare professional.